Elite in Hepatitis C

Dr. Joseph Lim

Gastroenterology
Nuvance Health Medical Practice Ct Inc
40 Cross St, 
Norwalk, CT 
Offers Telehealth
23 Years of Experience
Elite in Hepatitis C
Nuvance Health Medical Practice Ct Inc
40 Cross St, 
Norwalk, CT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joseph Lim is a Gastroenterologist in Norwalk, Connecticut. Dr. Lim has been practicing medicine for over 23 years and is rated as an Elite provider by MediFind in the treatment of Hepatitis C. His top areas of expertise are Hepatitis C, Hepatitis, Hepatitis B, Liver Transplant, and Endoscopy.

His clinical research consists of co-authoring 215 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 88 articles and participated in 3 clinical trials in the study of Hepatitis C.

Specialties
Gastroenterology
Licenses
Internal Medicine in CT
Hospital Affiliations
Yale-New Haven Hospital
Norwalk Hospital
Bridgeport Hospital
Greenwich Hospital Association -
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 1 Less Insurance Carrier -

Locations

NUVANCE HEALTH MEDICAL PRACTICE CT INC
40 Cross St, Norwalk, CT 06851
Other Locations
YALE UNIVERSITY
40 Temple St, New Haven, CT 06510
YALE UNIVERSITY
6 Devine St, North Haven, CT 06473
YALE UNIVERSITY
800 Howard Ave, New Haven, CT 06519
YALE UNIVERSITY
20 York St, New Haven, CT 06510
NUVANCE HEALTH MEDICAL PRACTICE CT INC
24 Hospital Ave, Danbury, CT 06810

Additional Areas of Focus

Dr. Lim has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
Enrollment Status: Terminated
Publish Date: September 17, 2025
Intervention Type: Other
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network - A Longitudinal, Observational Study.
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network - A Longitudinal, Observational Study.
Enrollment Status: Completed
Publish Date: February 28, 2024
A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)
A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Drug
Study Drugs: Lonafarnib, Ritonavir, PEG IFN-alfa-2a
Study Phase: Phase 3
THE PRIORITIZE STUDY: A Pragmatic, Randomized Study of Oral Regimens for Hepatitis C: Transforming Decision-Making for Patients, Providers, and Stakeholders
THE PRIORITIZE STUDY: A Pragmatic, Randomized Study of Oral Regimens for Hepatitis C: Transforming Decision-Making for Patients, Providers, and Stakeholders
Enrollment Status: Completed
Publish Date: December 06, 2021
Intervention Type: Drug
Study Phase: Phase 4
The Patient-Reported Outcomes Project of HCV-TARGET (PROP UP)
The Patient-Reported Outcomes Project of HCV-TARGET (PROP UP)
Enrollment Status: Completed
Publish Date: September 16, 2019
View 5 Less Clinical Trials

215 Total Publications

Impact of gender and age on the histologic severity of metabolic syndrome associated steatohepatitis.
Impact of gender and age on the histologic severity of metabolic syndrome associated steatohepatitis.
Journal: Human pathology
Published: October 07, 2025
Similar Doctors
Distinguished in Hepatitis C
Dr. Annmarie H. Liapakis
Transplant Surgery | Gastroenterology
Distinguished in Hepatitis C
Dr. Annmarie H. Liapakis
Transplant Surgery | Gastroenterology

New York University

317 E 34th St, 
New York, NY 
 (38.9 miles away)
212-263-6419
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Annmarie Liapakis is a Transplant Surgeon and a Gastroenterologist in New York, New York. Dr. Liapakis is rated as a Distinguished provider by MediFind in the treatment of Hepatitis C. Her top areas of expertise are Hepatitis C, Hepatitis, Visceromegaly, Liver Transplant, and Kidney Transplant.

Distinguished in Hepatitis C
Dr. John F. Reinus
Gastroenterology
Distinguished in Hepatitis C
Dr. John F. Reinus
Gastroenterology

Montefiore Medical Center

111 E 210th St, 
Bronx, NY 
 (29.2 miles away)
Languages Spoken:
English
See accepted insurances

John Reinus is a Gastroenterologist in Bronx, New York. Dr. Reinus is rated as a Distinguished provider by MediFind in the treatment of Hepatitis C. His top areas of expertise are Hepatitis, Autoimmune Hepatitis, Hepatitis C, Visceromegaly, and Liver Transplant.

Distinguished in Hepatitis C
Dr. Vivek A. Lingiah
Geriatrics | Gastroenterology
Distinguished in Hepatitis C
Dr. Vivek A. Lingiah
Geriatrics | Gastroenterology

University Physician Associates Of New Jersey Inc

90 Bergen St, 
Newark, NJ 
 (48.1 miles away)
973-972-5004
Experience:
17+ years
Languages Spoken:
English, French, Kannada
See accepted insurances
Accepting New Patients

Vivek Lingiah is a Geriatrics specialist and a Gastroenterologist in Newark, New Jersey. Dr. Lingiah has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of Hepatitis C. His top areas of expertise are Hepatitis, Hepatitis C, Visceromegaly, Enlarged Liver, and Endoscopy. Dr. Lingiah is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lim's expertise for a condition
ConditionClose
View All 27 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile